Human Immunodeficiency Virus Clinical Trial
Official title:
Neurovascular Magnetic Resonance Imaging in the Assessment of HIV-Associated Neurocognitive Disorders
Verified date | April 4, 2018 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Human immunodeficiency virus (HIV) infection appears to cause problems with blood vessel
function. These problems may add to some thinking and mood disorders found in people with HIV
infection. Researchers want to evaluate HIV infected patients to see if blood vessel function
contributes to thinking and mood disorders, such as early dementia and depression. To do so,
they will compare study results between people with and people without HIV infection.
Objectives:
- To compare the thickness of blood vessel walls between people with and without HIV
infection.
- To study the relationship between blood vessel thickness and thinking and mood
disorders.
Eligibility:
- Individuals between 25 and 55 years of age who have HIV infection.
- Healthy individuals between 25 and 55 years of age.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected.
- Participants will have imaging studies of the brain and major blood vessels in the head
and neck.
- Participants will also have neuropsychological testing. These tests will look at memory,
learning and thinking ability, attention, and mood.
- Participants will have the option of coming back for repeat blood tests every six months
and repeat imaging studies and neuropsychological tests every year, over 1- 4 years
period.
Status | Terminated |
Enrollment | 84 |
Est. completion date | April 4, 2018 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 25 Years to 61 Years |
Eligibility |
- INCLUSION CRITERIA: Inclusion criteria for all participants: 1. Age 25-61 years. 2. Willingness to allow stored samples, human leukocyte antigen (HLA) testing, and future genetic testing. 3. Hemoglobin less than or equal to 9.0 g/dL, HCT less than or equal to 28%, platelets less than or equal to 50,000/microL. 4. English language fluency (required for neuropsychological testing). Additional inclusion criteria for HIV+ participants: 1. Documented HIV infection by standard HIV testing. Prior documentation of HIV- antibody status at the NIH will be accepted in lieu of repeat testing. 2. HIV viral load below the limit of detection on combination antiretroviral therapy for less than or equal to 1 year. 3. Under the care of a primary care physician. Additional inclusion criteria for HIV-negative participants: 1. HIV-antibody negative. EXCLUSION CRITERIA: Exclusion criteria for all participants: 1. Contraindication to MRI scanning, including pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pump, or shrapnel fragments. 2. Subjects with a condition precluding entry into scanner and acquisition of scans (e.g., morbid obesity, claustrophobia, back pain, motion disorders). 3. Glomerular filtration rate <45 mL/min/1.73 m(2) as estimated using the Modified Diet in Renal Disease equation. 4. Allergy to qadolinium (MRI contrast) 5. Evidence of current or prior central nervous system opportunistic infection(s) and/or space-occupying lesions such as primary CNS lymphoma. 6. Prior history of intrathecal chemotherapy or radiation therapy to the brain. 7. History of or current diagnosis of systemic vasculitis. 8. Active systemic infection or malignancy requiring therapy. 9. Psychiatric condition interfering with ability to participate in study procedures or provide informed consent. 10. Patient or provider report of alcohol or drug abuse ongoing or within 3 months prior to participation. 11. Sickle cell disease (due to known association with vasculopathy). 12. Systolic blood pressure less than or equal to 180 mmHg at screening. 13. Persons infected with hepatitis C virus (HCV) who are being treated or planning to seek treatment for HCV. 14. Women who are lactating, pregnant, or actively seeking to become pregnant. 15. Other known clinical condition or conditions discovered on MRI that, at the discretion of the investigators, precludes serial clinical, neuropsychological, or imaging evaluation. Additional exclusion criteria for HIV+ participants 1. HIV acquired perinatally (due to potential effects of HIV and antiretroviral therapy on neurocognitive and vascular development). |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institutes of Health Clinical Center (CC) | National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Connor M. Human immunodeficiency virus (HIV) and stroke: targets for intervention. Infect Disord Drug Targets. 2010 Apr;10(2):76-83. Review. — View Citation
Highleyman L. Mortality trends: toward a new definition of AIDS? BETA. 2005 Winter;17(2):18-28. — View Citation
Holtgrave DR. Causes of the decline in AIDS deaths, United States, 1995-2002: prevention, treatment or both? Int J STD AIDS. 2005 Dec;16(12):777-81. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Neuropsychologic testing scores | 1-6 years | ||
Secondary | Serum biomarkers of cardiovascular disease and inflammation | 1-6 years | ||
Secondary | MRI brain and vascular findings | 1-6 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |